Hepatic uptake and clearance system

The hepatic uptake and clearance system is a coordinated network of basolateral and canalicular transporters and metabolic enzymes that manage the disposition of xenobiotics and endogenous molecules in the liver [1, 3]. Basolateral transporters, such as the Organic Anion Transporting Polypeptides (OATP1B1, OATP1B3) and Organic Cation Transporter 1 (OCT1), mediate the entry of drugs from the sinusoidal blood into hepatocytes [2, 5]. Once inside, substances may undergo Phase I and Phase II metabolism by enzymes like Cytochrome P450s and Uridine 5'-diphospho-glucuronosyltransferases (UGTs), or be directly excreted into the bile via canalicular efflux transporters like P-glycoprotein (MDR1), Multidrug Resistance-associated Protein 2 (MRP2), and the Bile Salt Export Pump (BSEP) [3, 5]. This system is a primary determinant of a drug's pharmacokinetics, including its half-life, bioavailability, and hepatic extraction ratio [9, 10]. Interference with these processes through drug-drug interactions or genetic variations can lead to toxicity, such as drug-induced liver injury (DILI) or hyperbilirubinemia [1, 12]. Consequently, this system is a critical focus in drug development for predicting systemic exposure and avoiding adverse reactions [6, 14].

Other names

Hepatic transport systemLiver uptake and efflux systemHepatocellular clearance systemHepatic drug disposition system

Competitive inhibition of uptake transporters (e.g., OATPs), transcriptional induction of metabolic enzymes (e.g., CYPs) and efflux pumps, and substrate-mediated transport into hepatocytes followed by biliary or sinusoidal excretion.